Clinical Trials · NCT07553988
A Comparative Dose-finding Study of RS-113 in Patients With Metastatic Castration-resistant Prostate Cancer
- Phase
- Phase 2
- Recruitment status
- Active Not Recruiting
- Sponsor
- R-Pharm International, LLC
- Enrollment
- 120
- Start date
- Oct 2024
- Locations
- 16 sites, Russia
- Primary endpoint
- Median Progression-free survival (PFS) at 1 year in RS-113 treatment arms